Roche is not in a rush to buy up Chugai; Merck's ex-innovation chief moves to Anthem subsidiary;

@FiercePharma: Could Zambian bats hold the key to curing Ebola? More | Follow @FiercePharma

@CarlyHFierce: Pfizer developing cholesterol-fighting vaccine as part of PCSK9 'franchise.' News | Follow @CarlyHFierce

> Roche ($RHHBY) said it is not in any hurry to buy the rest of Chugai Pharmaceutical that it doesn't already own and will instead continue to "fill gaps" in its portfolio and invest in Alzheimer's treatments. More

> Merck's ($MRK) ex-innovation chief, Dr. Sachin Jain, will begin work on Jan. 19 as chief medical officer of Anthem ($ANTM) subsidiary CareMore Health System. Story

> Roche is planning to sell its vacated property in Clifton, NJ, to Hackensack University Medical Center and Seton Hall University so the two can create a new medical facility. More

> Sumitomo Dainippon Pharma and its U.S. subsidiary Sunovion Pharmaceuticals jointly filed patent infringement lawsuits against Emcure Pharmaceuticals and InvaGen Pharmaceuticals over potential generic copies of its schizophrenia drug Latuda. Article

Medical Device News

@FierceMedDev: LabCorp-backed GeneCentric raising $20M Series B to build portfolio of molecular diagnostic tests. More | Follow @FierceMedDev

@VarunSaxena2: Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline. Story | Follow @VarunSaxena2

@EmilyWFierce: Bard loses bid to delay vaginal mesh trial proceedings. Article | Follow @EmilyWFierce

> What's next for next-gen sequencing? Everything. Editor's corner

> At JP Morgan, Stryker CEO embraces sales reps, dismisses Smith & Nephew plan to eliminate them. More

Biotech News

@FierceBiotech: The JP Morgan mood: Damn the valuations and full speed ahead in 2015. Article | Follow @FierceBiotech

@JohnCFierce: Enanta plots a future in NASH, chasing another blockbuster. Story | Follow @JohnCFierce

> The 2015 biotech takeover target list includes some hot new players. More

> Canadian VC CTI unveils a $112M new biotech fund. Story

> An inside look at the FDA's approach to speeding new drug approvals. Article

Vaccines News

> Late-stage trials for Glaxo, Merck Ebola jabs could begin this month in West Africa. Story

> WHO approves MenAfriVac for routine infant immunization in sub-Saharan Africa. Report

> J&J partners with AC Immune on anti-tau Alzheimer's vaccine. More

> Pfizer developing cholesterol-fighting vaccine as part of PCSK9 'franchise.' Article

> China approves world's first inactivated Sabin polio vaccine. Item

Pharma Manufacturing News

> Hospira to close Clayton, NC, production plant. Story

> Indian state hires FDA's online education provider to train inspectors. Article

> FDA links saline supply chain mixup to patient death. News

> Piramal lines up $40M investment in equipment and technology. Item

> New FDA quality office to grade manufacturing operations. More

> Boehringer mulls sale of generic plant as stateside shakeup continues. Report

And Finally… A new study shows that mice prevented from eating at all hours skirted obesity and metabolic problems, even if their diet was not entirely healthful. More (sub. req.)

Suggested Articles

In a high-stakes patent lawsuit between the CAR-T companies of Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.